
Assistant Professor of Rheumatology @uanl | LUMEN Research Collaborator @mayoclinic | Tweets are my own / 🐘☕🩺📖 / Left-handed.
25.68597,-100.346851
Joined June 2009
- Tweets2.3K
- Following1.5K
- Followers625
- Likes2.3K
Scientific Oath 🙋🏻♂️
I promise to work for a better world, where science and technology are used in socially responsible ways. I will not use my education for any purpose intended to harm human beings or the environment... 1/2
1
11
Gabriel Figueroa-Parra, MD, MSc retweeted
🆕 2025 ACR Guideline for Treatment of Systemic #Lupus Erythematosus 🦋
Just Released: Nov 3 #ACR25 🔥
🔸Review organ-specific treatment recommendations
🔸Steroid & HCQ Use Guidance
➠ Read the Full Guideline: acr.tw/47mkegj
#RheumX #RheumTwitter #Rheum @RheumNow
Gabriel Figueroa-Parra, MD, MSc retweeted
Now published: The 2025 ACR Guideline for the Treatment of Systemic Lupus Erythematosus
📄 Read the paper: acr.tw/47mkegj
ℹ️ See additional content and resources on this guideline at acr.tw/4mbHK4W

ALT LEGEND: Overview of the recommended management for systemic lupus erythematosus (SLE). This schematic illustrates the approach to SLE treatment, with organ-specific therapies presented in separate boxes and stratified by disease severity. The order of the medications in each box does not indicate preference unless noted otherwise. Lupus nephritis treatment is addressed in the 2025 American College of Rheumatology Guideline for the Screening, Treatment, and Management of Lupus Nephritis. (see paper for footnotes)
Gabriel Figueroa-Parra, MD, MSc retweeted
NEW! The ACR just released an updated clinical practice guideline for #SLE! Key recommendations include universal hydroxychloroquine use, lower steroid exposure, & earlier immunosuppressive therapy. Patient-centered care is central. READ MORE → acr.tw/4oAFS6q
Great summary! – at Monterrey, Nuevo León
NEW ACR clinical practice guideline provides recommendations regarding treatment of systemic lupus erythematosus (SLE) in both adults and children. FULL GUIDELINE → acr.tw/4mbHK4W #SLE #lupus
2
141
Gabriel Figueroa-Parra, MD, MSc retweeted
Honored to present our work at #ACR25:
“Differential Risk of Inpatient Admissions Among SLE Subgroups: A Population-Based Analysis.”
Grateful to my mentor @AliDuarteMD and the LUMEN team for their outstanding collaboration and guidance.
#Rheumatology #Lupus #LupusResearch
Gabriel Figueroa-Parra, MD, MSc retweeted
Congratulations to Eric L. Matteson, MD, MPH, recipient of the 2025 Presidential Gold Medal Award! @MayoClinic #ACR25
🚨🚨🚨
NEW #SLE clinical practice guideline to be unveiled at #ACR25! ✨
Don’t miss this important session—2025 American College of Rheumatology Guideline for the Treatment of Systemic Lupus Erythematosus, Saturday, Oct. 26, 9:00-10:30 AM CT. DETAILS → acr.tw/3WkE8SI
COMING SOON: Full guideline manuscript. Stay tuned 👀 → acr.tw/43u8XGi
77
Gabriel Figueroa-Parra, MD, MSc retweeted
YAP1-CCN2 signaling enables proproliferative communication between microvascular ECs and vascular SMCs in patients with antiphospholipid syndrome (APS) vasculopathy. Inhibiting the pathway could lead to a targeted treatment approach @RayZuoMD @DrGabrielFP ahajournals.org/doi/full/10.…
Gabriel Figueroa-Parra, MD, MSc retweeted
#ACR25 abstracts now online! 🎉 Browse over 3,100 abstracts representing the highest-impact research in the field of #rheum. NOTE: Information that goes beyond that contained in the abstract is under media embargo until Oct. 25 at 10:00 AM CT. View 👀 → acr.tw/30RaIzl
Gabriel Figueroa-Parra, MD, MSc retweeted
NEW EPISODE! Alain Sanchez-Rodriguez, MD, joins the podcast to discuss delays in #lupus diagnosis & care based on findings from the Lupus Midwest Network (LUMEN)🎙️LISTEN NOW → acr.tw/3UWKCXi @ACR_Journals
Gabriel Figueroa-Parra, MD, MSc retweeted
Thanks so much for this opportunity!!
sites.libsyn.com/436041/lume…
NEW EPISODE! Alain Sanchez-Rodriguez, MD, joins the podcast to discuss delays in #lupus diagnosis & care based on findings from the Lupus Midwest Network (LUMEN)🎙️LISTEN NOW → acr.tw/3UWKCXi @ACR_Journals
📢📢 Oficialmente, las guías 2024 del ACR para nefritis lúpica disponibles en extenso!!
Now published simultaneously in AC&R + A&R, the 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis
See ACR guideline page for resources - rheumatology.org/lupus-guide…
DOI link - doi.org/10.1002/acr.25528
Download the article - acr.tw/44sRwJM
177
I wasn't expecting this! 😮
Shout-out to @MariaCuellarMD, @AliDuarteMD, and all the team!
This Post is from an account that no longer exists. Learn more
📢📢📢Check out the new 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis!!!
Now available online: acrjournals.onlinelibrary.wi…
Gabriel Figueroa-Parra, MD, MSc retweeted
🚨🆕paper: #hypertension predicts #global and #renal #damage in #SLE #lupus data from the #AlmenaraLupusCohort @cientifica_sur @EsSaludPeru @PanlarLeague published in @SageHealthInfo journals.sagepub.com/doi/10.…
Gabriel Figueroa-Parra, MD, MSc retweeted
🚨New Research Alert 🚨
Excited to share our latest study in @TheLancetRheum
We analyzed the accuracy, quality, and safety of Large Language Models —ChatGPT-4, Claude 3: Opus and Gemini Advanced— in rheumatology board-like questions.
Read more:
thelancet.com/journals/lanrh…
Gabriel Figueroa-Parra, MD, MSc retweeted
Antiphospholipid Antibodies Linked to Increased Risk for Diffuse Alveolar Hemorrhage in SLE rheumatologyadvisor.com/news…
🧵 1/6 New research alert! 🚨 Our most recent LUMEN (💡) paper explores the utility of the 2019 EULAR/ACR SLE classification criteria in predicting mortality and hospitalization in patients with SLE. #LupusResearch #SLE. rmdopen.bmj.com/content/10/4…
This study is derived from my master’s degree thesis. I would like to thank my mentors @AliDuarteMD, @CrowsonCindy, and my TAC: Matthew J. Koster, MD, @LadanZand, and @mugartegil.
Also, thanks to all coauthors and funding sources that made this project possible.
1
3
207


























